%20(2).png){kind=logo}
The FDA's rollout of the AI tool "Elsa" was a predictable milestone in its broader, strategic shift toward generative AI-driven efficiencies in drug review processes, signaling the start of deeper transformative changes across regulatory operations.
The FDA's new generative AI tool, Elsa, is now accelerating clinical protocol reviews by summarizing data, identifying priorities, and streamlining workflows–marking a significant leap forward in regulatory review efficiency.
Havas today announced a strategic investment and partnership with Ostro, the trailblazing AI-powered engagement platform built for the life sciences industry
Ostro, the leading provider of AI-powered engagement solutions for life sciences, has filed a provisional U.S. patent application (US 19/036,907) titled "Machine Learning-Based Algorithms for Improved Generation of a Search Response."
Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to tee up personalized content.
Inside Chase Feiger's newest Forbes piece, he sits down with Giles Platford, President of the Takeda Plasma-Derived Therapies Business Unit, to discuss the challenges and breakthroughs shaping the future of PDTs.
Ostro, a leader in AI-driven digital engagement solutions, is proud to spotlight its partnership with the Desmoid Tumor Research Foundation (DTRF) as we approach Rare Disease Month, a meaningful time to foster awareness and champion impactful innovation.
.svg)